Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MZE829 in adults with APOL1 kidney disease
2024-517525-10-00Phase 2Authorised
- Sponsor
- Maze Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of MZE829 in APOL1-mediated kidney disease (AMKD) and chronic kidney disease (CKD), sponsored by Maze Therapeutics. Primary endpoint: Safety and tolerability. Planned start Sep 2025; status: authorised.
02
Drugs
MZE829
03
Conditions
APOL1-mediated kidney disease (AMKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-517525-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517525-10-00.